

VALIA & TIMBADIA
CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216
E-mail: valtim09@gmail.com
32, Trinity Chambers,
117, Bora Bazar Street, Fort,
Mumbai – 400 001.

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF SUN PHARMACEUTICALS KOREA LTD.

Report on the Financial Statements

We have audited the accompanying Ind AS Financial Statements of **SUN PHARMACEUTICALS KOREA LTD.** (the "Company"), which comprise the Balance Sheet as at March 31, 2017 and the Statement of Profit and Loss (including other Comprehensive income) and Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Management of the Company is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the Accounting Standards and Accounting Principles generally accepted in India. The responsibility includes the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation and fair presentation of the financial statements, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management of the Company, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion these financial statements.

VALIA & TIMBADIA
CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216
E-mail: valtim09@gmail.com
32, Trinity Chambers,
117, Bora Bazar Street, Fort,
Mumbai – 400 001.

Emphasis of Matters

The Net Worth of the Company has been fully eroded; however in the opinion of the management, the going concern of the company will not be affected.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the financial position of the Company as at 31 March, 2017, and its financial performance including other comprehensive income and the changes in equity for the year ended on that date.

FOR VALIA AND TIMBADIA
CHARTERED ACCOUNTANTS
(Firm Registration No. 112241W)

HITEN C. TIMBADIA
Partner
Membership No. 038429.

PLACE: MUMBAI
DATED: 22nd May, 2017.

SUN PHARMACEUTICALS KOREA LTD.

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH, 2017

REVENUE

Income

EXPENDITURE

Expenses

Other Expense

Audit Fees
Foreign Exchange Loss/gain
Professional and Consultancy
Net Gain/ (Loss)

<u>31.03.2017</u> <u>KRW</u>	<u>31.03.2016</u> <u>KRW</u>
-	-
246,248	251,372
(486,523)	483,853
5,412,563	2,106,634
(5,172,288)	(2,841,859)

For **Valia & Timbadia**
Chartered Accountants
Firm Reg. No . 112241W

For and on behalf of the Board

(Hiten C. Timbadia)
Partner
Membership No. 038429
Place: Mumbai
Date:

Rajesh Shah
Director
Place:
Date:

Surendra Joshi
Director
Place:
Date:

Statement of changes of changes of Equity for the year ended 31st March, 2017

<u>Retained Earnings</u>	Amount in KRW
Balance as on April 1, 2015	(19,022,786)
Profit for the year	(2,841,859)
Other comprehensive income for the year, net of income tax	0
Total comprehensive income for the year	(2,841,859)
Balance as at March 31, 2016	(21,864,645)
Profit for the year	(5,172,288)
Other comprehensive income for the year, net of income tax	0
Total Comprehensive income for the year	(5,172,288)
Balance as at March 31,2017	(27,036,933)

For **Valia & Timbadia**
Chartered Accountants
Firm Reg. No . 112241W

For and on behalf of the Board

(Hiten C. Timbadia)
Partner
Membership No. 038429
Place: Mumbai
Date:

Rajesh Shah
Director
Place:
Date:

Surendra Joshi
Director
Place:
Date:

SUN PHARMACEUTICALS KOREA LTD.

Notes forming part of the financial statement for the year ended 31st March, 2017

1. SHARE CAPITAL

Sun Pharma Global FZE is holding 100% shares in the Company.

The shareholder and its shareholding in the company is as under:-

Particulars	No. of Shares	Share Value
Opening Balance	1,000,000	1,000,000,000
Addition during the year	0	0
Closing Balance	1,000,000	1,000,000,000

2 LEGAL STATUS

Sun Pharma Korea Ltd was Incorporated on 20th September, 2011 in Korea and the company number is 110111-4690487

The Directors of the company are as under:-

<u>Name of the Director</u>	<u>Nationality</u>	<u>Position</u>
Mr Surendra Joshi	Indian	Director
Mr Rajesh Shah	Indian	Director

3 ACTIVITY

The Company has not commenced any commercial activity till date.

4 ACCOUNTING POLICY

The Financial statements has ben prepared under historical cost convention on an accrual basis and comply with Indian Accounting standards (Ind AS) notified under the companies Rules, 2015 together with the comparative period data as at and for the year ended March 31, 2016.

5 Interest free loan taken from the Parent company is not discounted at Fair value and shown as per historical cost as decided by the management

6 Related Party Transaction

Name of the Company	Relationship	Transaction	31.03.2017	31.03.2016
			Amount in KRW	Amount in KRW
Sun Pharma Global FZE	Holding company	Long Term Borrowing	27,911,114	22,757,164

5 Previous year's figures are regrouped wherever necessary to make them comparable with current year's figures.

**For Valia & Timbadia
Chartered Accountants
Firm Reg. No . 112241W**

For and on behalf of the Board

(Hiten C. Timbadia)
Partner
Membership No. 038429
Place: Mumbai
Date:

Rajesh Shah
Director
Place:
Date:

Surendra Joshi
Director
Place:
Date :

BOARD OF DIRECTORS' REPORT

The Board of Directors submit its Annual Report together with the audited financial statements for the year ended 31st March, 2017

Operations:

The Company has not commenced any commercial activity till date.

Capital:

The authorised, issued and paid-up capital of the Company is 4000000 Ordinary shares of KRW 100 each

Directors:

The Directors who served during the year was as follows:

Mr Surendra Joshi
Mr Rajesh Shah

**For Valia & Timbadia
Chartered Accountants
Firm Reg. No . 112241W**

For and on behalf of the Board

(Hiten C. Timbadia)
Partner
Membership No. 038429
Place: Mumbai
Date:

Rajesh Shah
Director
Place:
Date:

Surendra Joshi
Director
Place:
Date :